Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
PASADENA, Calif.–(BUSINESS WIRE)–May 1, 2018–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it
will present preclinical data on ARO-ANG3 and ARO-APOC3, its two
candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly
referred to as ARO-Lung1, its first candidate to leverage the Targeted
RNAi Molecule (TRiMTM) platform to address diseases in the
lung. Arrowhead will deliver presentations at the following conferences:
Vascular Discovery: From Genes to Medicine – Scientific Sessions 2018 –
San Francisco, May 10-12, 2018
May 10, 4:15 p.m. PDT –Bruce Given, M.D., Arrowhead’s chief
operating officer and head of R&D, will deliver an invited lecture
titled, “The promise of RNA interference as a therapeutic approach
for treatment of cardiovascular diseases.” In this presentation, Dr.
Given will discuss the use of RNAi broadly in treating cardiovascular
diseases, including preclinical data on ARO-ANG3 targeting
angiopoietin-like protein 3 (ANGPTL3) and ARO-APOC3 targeting
apolipoprotein C-III (apoC-III), Arrowhead’s preclinical candidates for
the treatment of cardiometabolic diseases.
American Thoracic Society (ATS) 2018 International Conference–
San Diego, May 18-23, 2018
May 21, 9:15 a.m.-4:15 p.m. PDT –Erik Bush, Ph.D., Arrowhead’s
director of extra-hepatic targeting, will deliver a poster presentation
titled, “Targeting αENaC with an epithelial RNAi trigger delivery
platform for the treatment of cystic fibrosis.” In this
presentation, Dr. Bush will present new preclinical data on ARO-ENaC,
formerly referred to as ARO-Lung1, targeting the epithelial sodium
channel alpha subunit (αENaC) for the treatment of cystic fibrosis.
A copy of presentation materials may be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website after the presentations conclude.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501005558/en/
Source: Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie, 212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com